While progesterone has shown promise in modulating the efficacy of endocrine therapies such as tamoxifen, fulvestrant, and giredestrant against ESR1-mutant breast cancer, the outcomes of such treatments have also been pro-tumorigenic [41]. Here, ESR1 is linked to breast cancer.